Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,102 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 9,102 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.40. The trade was a 7.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Trading Down 0.3 %

NASDAQ:MIRM traded down $0.17 on Friday, hitting $51.06. 616,405 shares of the stock were exchanged, compared to its average volume of 532,217. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $53.49. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -25.28 and a beta of 0.96. The company's 50-day moving average price is $44.80 and its 200 day moving average price is $42.31.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analysts' expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business's revenue for the quarter was up 89.4% on a year-over-year basis. During the same period last year, the firm earned ($0.57) earnings per share. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after acquiring an additional 318 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the period. Legato Capital Management LLC grew its holdings in shares of Mirum Pharmaceuticals by 7.9% in the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock valued at $554,000 after buying an additional 977 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after buying an additional 1,003 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Mirum Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock worth $2,196,000 after buying an additional 1,236 shares during the period.

Analysts Set New Price Targets

MIRM has been the topic of several analyst reports. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. HC Wainwright reiterated a "buy" rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners lifted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Finally, Citigroup increased their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.